Orphan Diseases Market is Resumed to Witness Promising Double-Digit CAGR of 24.9% During Forecast to 2022
Market-Overview:
An orphan disease is defined
as a disorder that affects fewer than 200,000 people in America annually. This
includes diseases as familiar as cystic fibrosis, Lou Gehrig's disease, and
Tourette's syndrome, and as unaware as Hamburger disease, Job syndrome, and
acromegaly, or "gigantism." Some diseases have patient populations of
less than a hundred. Mutually, however, they affect as many as 25 million
Americans every year, according to the National Institutes of Health (NIH), and
that makes the diseases--and finding treatments for them-a serious public
health concern.
New rare diseases are revealed
every year. Most are hereditary and caused by adjustments or defects in genes
(mutations). Others can be developed as a result of environmental and toxic
conditions. Genes are pieces of DNA, part of the code that regulates the traits
and discrete characteristics of all living things. Each human cell contains
around 30,000 genes. Besides impelling features such as eye and hair colour,
genes also can play a role in the development of diseases and in their
transmission from parent to child.
As distinct as rare diseases
are, patients share many common frustrations. For example, for one-third of
people with a rare disease, getting a precise diagnosis can take one to five
years. And people often are so isolated that they may never know anyone else
with the same disease. Patients often must travel long distances to visit the
few doctors knowledgeable about their diseases, and the costs involved with
diagnosis, treatment, and other related expenses can be inflated
Get a Free Sample
@ https://www.marketresearchfuture.com/sample_request/2547
Competitive
Landscape:
There are various players operating in the global Orphan
Diseases market, some of the major players are
·
Bristol-Myers Squibb Company
·
Novartis AG
·
CELGENE CORPORATION
·
F. Hoffmann-La Roche Ltd
·
Pfizer Inc
·
Alexion
·
Sanofi
·
Vertex Pharmaceuticals Incorporated
·
GlaxoSmithKline plc
·
Merck & Co
·
AbbVie Inc
Segments:
·
Global orphan diseases market has been segmented on
the basis of types of diseases which includes autoimmune disorders, genetic
disorders, blood disorders, cancer, growth disorder, cardiovascular diseases,
neurological disorders, respiratory disorders, digestive disorders, eye
disorders and others.
·
On the basis of treatment type it segmented into gene
therapy, cell therapy, drug therapy and others.
·
On the basis of end-user the market is segmented into
hospital and clinics, research laboratory and others.
Regional Analysis:
Depending on geographic region, Orphan diseases
Market is segmented into four key regions: Americas, Europe, Asia-Pacific, and
Middle East & Africa. Considering the global scenario of the market, North
America comprise largest market share in Orphan diseases. Moreover, the
European market is also growing continuously and slowly catching up with the
American market in the near future. On the other hand, Asia-Pacific market is
expected to grow at the fastest pace in the Orphan diseases segment during the
forecasted period. Rest of the World is likely to have a limited but steady
growth in the market.
Access
Full Report Details and TOC Exclusively @ https://www.marketresearchfuture.com/reports/orphan-diseases-market-2547
About Market Research
Future:
At Market Research Future (MRFR),
we enable our customers to unravel the complexity of various industries through
our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment